Wegovy Pen

What Is Wegovy and How Does It Work?

Wegovy is a prescription only weight loss injection, which contains the active ingredient semaglutide, a medication that helps regulate appetite and calorie intake. 

Semaglutide belongs to the class of medications GLP-1 receptor agonists, which mimic a natural gut hormone involved in hunger signalling and blood sugar control. Wegovy is approved for chronic weight management alongside a reduced calorie diet and increased physical activity. 

In addition to its effects on weight, semaglutide has also been studied for its impact on cardiovascular health. The SELECT cardiovascular outcomes trial found that semaglutide significantly reduced the risk of major adverse cardiovascular events; including heart attack, stroke, and cardiovascular death in adults with overweight or obesity and established cardiovascular disease, even in those without diabetes. This highlights that the benefits of Wegovy may extend beyond weight loss alone. 

How Wegovy works in the body

Wegovy supports weight loss by acting on several digestion and appetite pathways:

• Reduces hunger signals in the brain, helping you feel less hungry in between meals 

• Increases feelings of fullness (satiety) after eating 

• Delays stomach emptying, which helps you feel fuller for longer 

• Supports lower calorie intake over time when combined with lifestyle changes 

Appetite and satiety effects 

The active ingredient semaglutide targets areas of the brain involved in appetite regulation. Many people report: 

• Smaller portion sizes 

• Fewer food cravings

• Longer lasting fullness between and after meals 

These effects develop gradually as the weekly dose is increased under medical supervision. 

Wegovy vs diabetes uses of semaglutide 

Although Wegovy contains semaglutide, it is only licensed for weight management. Other semaglutide medicines ( such as Ozempic used in type 2 diabetes) are prescribed primarily to improve blood glucose control.

The key differences include: 

• Indication : Wegovy is approved for chronic weight management

• Dosing: Wegovy uses a higher target dose for weight loss 

• Treatment goal : weight reduction vs blood sugar control 

People with diabetes may still be prescribed semaglutide, but the brand, dose and clinical goals are different. 

Is Wegovy Approved in the UK?

Wegovy is approved for use in the UK for chronic weight management in eligible patients. Wegovy is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and officially received UK authorisation in September 2021, meaning it met standards for safety, quality and efficacy. 

In the UK regulatory approval is separate from NHS availability. After MHRA authorisation, Wegovy was evaluated by the National Institute for Health and Care Excellence (NICE), which assesses whether treatments should be recommended for NHS funding. 

In March 2023 , NICE recommended Wegovy for use within the NHS. The NHS currently provides specialist weight management services for certain patients with obesity.

Although the approval meant the medicine could legally be prescribed in the UK, access through the NHS is restricted to people who meet strict clinical criteria and are referred into specialist weight management services. Because of these limits, many eligible adults currently obtain Wegovy following a medical assessment, through private clinics or pharmacies such as Quick Meds.

Who Is Eligible for Wegovy in the UK?

In the UK, Wegovy is prescribed for adults with obesity and for some adults with weight related health conditions. Eligibility depends on clinical assessment, body mass index (BMI) and whether treatment is being accessed through the NHS or privately. 

Healthcare professionals use BMI to assess whether someone may benefit from weight loss treatment. Body mass index is used by the NHS as part of formal eligibility criteria. 

NHS eligibility criteria

Under current UK guidance, NHS access to Wegovy is limited to people referred to specialist weight management services and is used for a maximum of 2 years. In general patients must meet the following criteria:

• At least one weight related health condition

• a BMI of 35 or above (lower thresholds may apply for some ethnic groups)

• a BMI of 30-34.9 and meets referral criteria (lower thresholds may apply for some ethnic groups)

Private clinic criteria

Private weight management clinics often follow similar clinical principles but typically offer broader access. Many UK providers may prescribe Wegovy to adults who have: 

• a BMI of 30 kg/m² or above, or

• a BMI of 27 kg/m² or above with a weight-related condition

A medical consultation is still required to confirm suitability and safety. 

Weight related health condition that may qualify someone 

Obesity increases the risk of type 2 diabetes and several other health problems. Other weight related conditions that may support eligibility include high blood pressure, sleep apnoea, cardiovascular risk factors and pre diabetes. 

Because criteria and local NHS Pathways can vary, anyone considering Wegovy should speak with a qualified healthcare professional for personalised advice.

Wegovy Dosage Schedule Explained

Wegovy is administered as a weekly injection and should be taken on the same day each week. The dose is increased gradually over several months to help the body adjust to treatment, improve tolerability and reduce side effects. 

Treatment starts at the lowest strength and healthcare professionals follow a structured dose-escalation plan until the maintenance dose is reached. Wegovy dosage is increased to the maintenance dose step by step because dose escalation reduces side effects such as nausea, vomiting, diarrhoea, constipation and stomach upset. 

Weekly dosage schedule 

1. Weeks 1–4: 0.25mg once weekly

2. Weeks 5–8: 0.5mg once weekly

3. Weeks 9–12: 1mg once weekly

4. Weeks 13–16: 1.7mg once weekly

5. Week 17- 20: 2.4mg once weekly 

6. Week 21 onwards : 7.2mg once weekly

Not everyone will progress at the same pace. Your prescriber may recommend delaying your dose increase if you are experiencing side effects or need more time to adjust. 

Why the dose increases slowly

Gradual dose escalation helps the body adapt to the treatments effects on appetite and digestion. This approach is designed to improve tolerability and reduce the likelihood of gastrointestinal side effects, particularly in the early stages of treatment.

Key reminders for patients 

• Take a full dose of Wegovy on the same day each week every 7 days 

• It can be taken with or without food

• If you miss a dose and it is within 5 days, take it as soon as possible

• Do not increase the dose faster than your prescriber advises

• Always follow clinician advice

How Much Weight Can You Lose With Wegovy?

Wegovy has been studied in clinical trials for adults with obesity or overweight. These clinical trials show average percentage body weight loss of approximately 17% of starting body weight on the licensed 2.4 mg maintenance dose over 68 weeks.

Higher dosing, such as 7.2 mg per month, has been studied in clinical trials and showed average weight loss of up to 21 % of starting body weight over 72 weeks.

How long does it take to see results?

People typically notice appetite changes in the first few weeks of starting Wegovy. Gradual, sustained weight loss continues over months, with the most significant changes often seen after approximately 15 months of consistent treatment combined with diet and lifestyle support.

Factors that influence outcomes

Weight loss results vary by adherence and lifestyle, and may be affected by:

• Following the prescribed weekly injection schedule

• Maintaining a reduced-calorie diet

• Staying physically active

• Individual metabolic differences and health conditions

As everyone responds differently, it’s impossible to guarantee exact weight loss. Combining medication with lifestyle modifications such as diet and exercise gives the best chance of achieving clinically studied outcomes safely.

Wegovy Side Effects and Safety

Wegovy may cause nausea and other side effects, particularly when initiating treatment or increasing the dose. As a part of the GLP-1 receptor agonists family, Wegovy affects the gastrointestinal system, which explains why nausea, vomiting, and changes in bowel habits are commonly reported.

Common side effects

Gastrointestinal side effects are the most frequent and include:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Abdominal discomfort or bloating

Other common side effects may include headache, fatigue, dizziness, and mild injection-site reactions. These common side effects usually decrease as the body adjusts to the treatment. 

Serious but rare risks

While uncommon, more serious side effects require immediate medical attention. These include:

• Gallstones: Signs include severe abdominal pain, particularly in the upper right area

• Acute pancreatitis: Symptoms include severe abdominal pain that radiates to the back, along with nausea and vomiting

• Severe allergic reactions: Including difficulty breathing, swelling of the face or throat, and severe rash

• Kidney problems: Particularly in those with existing kidney conditions

Monitoring and safety

Side effects will be closely monitored by a prescribing clinician to ensure treatment remains safe. Gradual dose escalation helps minimise these side effects by allowing the body time to adjust at each dose.

Patients should contact their healthcare professional promptly if they experience any concerning symptoms. This monitoring ensures that Wegovy is used safely alongside lifestyle modifications for weight management.

Wegovy vs Other Weight Loss Injections

Wegovy can be compared with Mounjaro and Saxenda. All three are prescription-only in the UK and work alongside a healthy diet and exercise for weight management.

Practical considerations

• Frequency and convenience: Weekly injections may be easier to adhere to than daily dosing.

• Regulatory status: All three are licensed in the UK, but NICE guidance differs for NHS prescribing.

• Patient choice: Selection depends on lifestyle, medical history, and clinician recommendations rather than assuming one medication is universally superior.

Can You Get Wegovy on the NHS?

In the UK, Wegovy is available through specialist services but access through the NHS is limited. The NHS offers Wegovy typically only via Tier 3 weight management services, which provide intensive support including medication, dietary guidance, and behavioural interventions. 

Prior to reaching Tier 3, patients generally should have tried to attempt or complete a Tier 2 community based weight management programme. Tier 2 focuses on lifestyle changes, diet and physical activity. 

Patients wishing to access Wegovy on the NHS usually require a GP to refer patients to a weight management programme. Tier 3 services have strict eligibility criteria, such as BMI thresholds and weight-related health conditions, and waiting lists can be long due to high demand and limited resources.

As a result, not everyone who meets clinical criteria will receive treatment via the NHS immediately, and access is often slower compared to the private market. Those unable to obtain treatment through the NHS may consider private prescriptions, from pharmacies such as Quick Meds which can provide faster access but involve direct costs.

Getting Wegovy Privately in the UK

As a prescription-only medicine, Wegovy can only be supplied following a full clinical assessment to confirm eligibility and suitability. Treatment is most effective when patients follow prescribers advice and are used alongside healthy lifestyle changes.

In the UK, private clinics and regulated online pharmacies are able to prescribe Wegovy, provided appropriate clinical checks are completed. All reputable providers will require a detailed health questionnaire and clinician review before issuing a prescription, as Wegovy requires a medical assessment to ensure safe use.

At Quick Meds, all treatment requests are reviewed by our in-house prescribers to confirm the medication is appropriate. As a UK-based online pharmacy registered and regulated by the General Pharmaceutical Council, the service we provide is regularly inspected to ensure pharmacy standards and patient safety requirements are met.

Once prescribed, our prescribing clinician monitors patient progress, with ongoing support available if questions or side effects arise. Prescriptions are dispensed, securely/discreetly packaged, and delivered via tracked services to most UK addresses.

Patients considering private treatment should prioritise regulated providers that offer:

• Proper clinical screening before prescribing

• Ongoing monitoring and follow-up

• Transparent pricing and supply information

Accessing Wegovy privately can be faster than NHS routes, but safety checks and medical oversight remain essential to ensure treatment is safe, appropriate and effective.

Wegovy Cost in the UK

Wegovy costs between £135 and £299 per month in the UK, and is variable depending on your dose and the provider you choose. The 0.25mg starting dose normally begins from around £135, while higher maintenance doses generally cost more. 

Wegovy is a prescription only weight loss injection in the UK, and prices are set privately rather than through the NHS. Within the advertised monthly price most online pharmacies such as Quick Meds include the cost of an online medical consultation, prescriber approval, medication and temperature controlled delivery. In most cases, private prescriptions include medication and support as part of the monthly fee.

Introductory doses such as 0.25 mg and 0.5 mg usually sit at the lower end of the range, while maintenance and higher strength doses now reaching up to 7.2 mg are priced higher due to increased medication volume and demand.

Wegovy is available from private clinics as well as online pharmacies such as Quick Meds. Prices can vary notably between providers, with online pharmacies often proving more cost effective than in person private clinics. Where Wegovy is prescribed through the NHS, prescriptions may reduce patient cost, but access remains limited and subject to eligibility criteria.

Recent price increases across competing GLP-1 medications such as Mounjaro in late 2025 have also made Wegovy comparatively more competitive for long term monthly treatment.

Lifestyle Changes Needed With Wegovy

Wegovy works best with sustainable lifestyle changes. Weight management includes a combination of dietary adjustments, regular exercise, and behavioural support to help sustain results over the long term.

Behaviour change strategies, such as setting goals, self-monitoring, and structured support, can significantly support long-term weight loss and help patients maintain the benefits even after treatment. Incorporating these strategies alongside Wegovy helps maximise the effectiveness of the medication. 

Recommended lifestyle adjustments may include:

• Following a balanced, calorie appropriate diet

• Engaging in regular aerobic and strength-based exercise

• Tracking food intake and activity levels

• Using behavioural support tools such as goal setting or habit tracking